AbbVie’s Q4 revenue grew 2% and EPS beat consensus. Considering Humira US sales erosion of 37%, the company anticipates 2023 EPS of $10.70–11.10. AbbVie is on track to return to robust growth in 2025.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.